Pharmacotherapy for Perinatal Depression

Shari I. Lusskin, Sabrina J. Khan, Carrie Ernst, Sally Habib, Madeleine E. Fersh, Elizabeth S. Albertini

Research output: Contribution to journalReview articlepeer-review

13 Scopus citations


Perinatal depression is associated with serious risks for the mother, baby, and family. When considering treating perinatal depression with a drug indicated for the treatment of depression, the major concerns are whether the drug increases the risks of teratogenicity, pregnancy complications, poor neonatal adaptation, or neurodevelopmental disorders. Although different studies have produced different results, the majority have not shown increases in risk for selective serotonin reuptake inhibitors, serotonin norepinephrine reuptake inhibitors, tricyclic antidepressants, or the noradrenergic/dopaminergic drug bupropion. In this review we will discuss the reproductive safety data for these medications as well as monoamine oxidase inhibitors and benzodiazepines.

Original languageEnglish
Pages (from-to)544-561
Number of pages18
JournalClinical Obstetrics and Gynecology
Issue number3
StatePublished - 1 Sep 2018


  • antidepressants
  • autism
  • breastfeeding
  • depression
  • neonatal complications
  • neurodevelopment
  • perinatal
  • pregnancy
  • teratogenicity


Dive into the research topics of 'Pharmacotherapy for Perinatal Depression'. Together they form a unique fingerprint.

Cite this